Predictors of response to opicinumab in acute optic neuritis

D Cadavid, L Balcer, S Galetta, O Aktas, T Ziemssen, LJ Vanopdenbosch, L Leocani, MS Freedman, GT Plant, JL Preiningerova, F Ziemssen, L Massacesi, Y Chai, L Xu, on behalf of the RENEW Study Investigators

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: The objective of this study was to evaluate prespecified and post hoc analyses in RENEW subgroups to identify participants more likely to benefit from opicinumab. Methods: RENEW assessed the efficacy/safety of opicinumab versus placebo in participants with a first unilateral acute optic neuritis (AON) episode. Difference in visual evoked potential (VEP) latency of the affected eye at 24 weeks versus the fellow eye at baseline was the primary endpoint. Interactions between the primary endpoint and prespecified baseline variables (including age, timing of treatment initiation, and visual impairment) using the median as cut-off were evaluated in the per protocol population using analysis of covariance (ANCOVA); subgroups based on preexisting brain T2 lesion volume were also analyzed. Interactions between the primary endpoint and retinal ganglion cell layer/inner plexiform layer (RGCL/IPL) and retinal nerve fiber layer (RNFL) thickness were assessed post hoc as was weight gain by treatment. Results: Treatment benefit of opicinumab (n = 33) over placebo (n = 36) on the primary endpoint was greatest in participants older than the median age at baseline (≥33 years); the difference versus placebo for baseline age ≥33 years was −14.17 msec [P = 0.01] versus −0.89 msec for baseline age
Original languageEnglish
Pages (from-to)1154-1162
Number of pages9
JournalAnnals of Clinical and Translational Neurology
Volume5
Issue number10
DOIs
Publication statusPublished - 2018

Fingerprint Dive into the research topics of 'Predictors of response to opicinumab in acute optic neuritis'. Together they form a unique fingerprint.

Cite this